Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Executive Summary
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says